ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

MNKD MannKind Corporation

4.40
0.29 (7.06%)
After Hours
Last Updated: 23:00:18
Delayed by 15 minutes
Share Name Share Symbol Market Type
MannKind Corporation NASDAQ:MNKD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.29 7.06% 4.40 4.23 4.35 4.3925 4.15 4.19 2,507,006 23:00:18

Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7

03/06/2022 3:00pm

GlobeNewswire Inc.


MannKind (NASDAQ:MNKD)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more MannKind Charts.

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will showcase its mealtime insulin solutions and expanding efforts within the diabetes community at the American Diabetes Association’s 82nd Scientific Sessions, June 3-7 in New Orleans.

“MannKind is committed to providing products that address unmet needs for patients living with diabetes,” said Alejandro Galindo, Executive Vice President, Endocrine Business Unit for MannKind Corporation. “This effort is demonstrated by our growing portfolio of products, including Afrezza® and V-Go®, that change the way diabetes is managed.”

When the exhibit hall opens at ADA, MannKind will host a booth (Booth #1019) to share information about its expanding diabetes products, host meetings with health care professionals (HCPs). MannKind will also publish an abstract on “Augmenting Clinical Trial Data within Silico Evidence to Evaluate Initial Conversion Dose Changes for Technosphere® Insulin (TI).” The abstract will be published in category 12-E Clinical Therapeutics/New Technology – Insulins.

MannKind will present a Product Theater event (product theater #3) on Saturday, June 4 at 4:30 p.m. (ET) discussing “Ultra Rapid-Acting Inhaled Insulin for Diabetes Management.” Dr. Kevin Kaiserman, Vice President, Medical Affairs & Safety, Endocrine Business Unit for MannKind Corporation, will be joined by Dr. Steven Edelman and Dr. Jeremy Pettus of Taking Control Of Your Diabetes (TCOYD) to speak during the program.

About MannKind CorporationMannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of convenient and therapeutic products for patients with endocrine and orphan lung diseases. MannKind was established in 1991, and is located in Danbury, Conn., Marlborough, Mass., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more and follow us on LinkedIn, Facebook, Twitter or Instagram.

AFREZZA, MANNKIND, TECHNOSPHERE, V-GO and the MannKind logo are registered trademarks of MannKind Corporation.

MANNKIND CONTACTS:Christie Iacangelo, Corporate Communications (818) 292-3500        Email: media@mannkindcorp.com        

Rose Alinaya, Investor Relations(818) 661-5000Email: ir@mannkindcorp.com

1 Year MannKind Chart

1 Year MannKind Chart

1 Month MannKind Chart

1 Month MannKind Chart

Your Recent History

Delayed Upgrade Clock